Nasdaq

Daré Bioscience Secures $6 Million Funding to Advance DARE-LARC1 Contraceptive Development

Daré Bioscience secures $6 million funding for DARE-LARC1, a contraceptive leveraging advanced drug delivery technology, totaling $37.8 million received. Daré Bioscience, Inc. has announced the ...
Seeking Alpha

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform ...

SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today ...
Nasdaq

Daré Bioscience Receives Up to $2 Million Grant from NIAID to Support Development of Innovative DARE-HPV Treatment for Cervical Disease

DARE-HPV is a proposed treatment for HPV-related cervical diseases, supported by up to $2 million in NIAID grants. Daré Bioscience, Inc. has announced the development of DARE-HPV, an investigational ...